Glucose-regulated protein 78 Is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma

Jeng-Fong Chiou, Cheng-Jeng Tai, Ming-Te Huang, Po-Li Wei, Yu Huei Wang, Jane An, Chih-Hsiung Wu, Tsan Zon Liu, Yu-Jia Chang

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background: Sorafenib is a newly established cancer drug found to be an effective systemic treatment for advanced hepatocellular carcinoma (HCC). However, little is known about any potential effectors that modify tumor cell sensitivity towards sorafenib. Here, we present the first evidence that glucose-regulated protein 78 (GRP78) is intimately associated with acquisition of resistance towards sorafenib. Methods: The role of GRP78 in acquisition of resistance towards sorafenib was determined using HepJ5 (a GRP78-overexpressing subline) and HepG2 as its pair-matched control. RNA interference in cancer cells was applied to determine the influence of GRP78 expression on sensitivity to sorafenib treatment. Results: We found that HepG2 cells exhibited higher sensitivity toward sorafenib, with 50% inhibition concentration (IC 50) >20 μΜ for HepJ5 and 4.8 μM for HepG2. Specifically, when HepG2 cells received 20 μM sorafenib treatment for 24 h, over 80% of cells underwent apoptosis compared with only 32% of HepJ5 cells under similar experimental conditions. Similarly, GRP78 knockdown in HepJ5 cells by small interfering RNA (siRNA) technique enhanced the efficacy of sorafenib-mediated cell death. This was reflected by a shift of IC50 values from >20 μM to 4.8 μM. Conclusions: GRP78 is a positive modifier for sorafenib resistance acquisition in HCC and represents a prime target for overcoming sorafenib resistance.

Original languageEnglish
Pages (from-to)603-612
Number of pages10
JournalAnnals of Surgical Oncology
Volume17
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Hepatocellular Carcinoma
Hep G2 Cells
sorafenib
glucose-regulated proteins
Neoplasms
RNA Interference
Small Interfering RNA
Inhibitory Concentration 50
Cell Death
Apoptosis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Glucose-regulated protein 78 Is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. / Chiou, Jeng-Fong; Tai, Cheng-Jeng; Huang, Ming-Te; Wei, Po-Li; Wang, Yu Huei; An, Jane; Wu, Chih-Hsiung; Liu, Tsan Zon; Chang, Yu-Jia.

In: Annals of Surgical Oncology, Vol. 17, No. 2, 02.2010, p. 603-612.

Research output: Contribution to journalArticle

@article{0d298a67d5dd430f81c03d674541e5ea,
title = "Glucose-regulated protein 78 Is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma",
abstract = "Background: Sorafenib is a newly established cancer drug found to be an effective systemic treatment for advanced hepatocellular carcinoma (HCC). However, little is known about any potential effectors that modify tumor cell sensitivity towards sorafenib. Here, we present the first evidence that glucose-regulated protein 78 (GRP78) is intimately associated with acquisition of resistance towards sorafenib. Methods: The role of GRP78 in acquisition of resistance towards sorafenib was determined using HepJ5 (a GRP78-overexpressing subline) and HepG2 as its pair-matched control. RNA interference in cancer cells was applied to determine the influence of GRP78 expression on sensitivity to sorafenib treatment. Results: We found that HepG2 cells exhibited higher sensitivity toward sorafenib, with 50{\%} inhibition concentration (IC 50) >20 μΜ for HepJ5 and 4.8 μM for HepG2. Specifically, when HepG2 cells received 20 μM sorafenib treatment for 24 h, over 80{\%} of cells underwent apoptosis compared with only 32{\%} of HepJ5 cells under similar experimental conditions. Similarly, GRP78 knockdown in HepJ5 cells by small interfering RNA (siRNA) technique enhanced the efficacy of sorafenib-mediated cell death. This was reflected by a shift of IC50 values from >20 μM to 4.8 μM. Conclusions: GRP78 is a positive modifier for sorafenib resistance acquisition in HCC and represents a prime target for overcoming sorafenib resistance.",
author = "Jeng-Fong Chiou and Cheng-Jeng Tai and Ming-Te Huang and Po-Li Wei and Wang, {Yu Huei} and Jane An and Chih-Hsiung Wu and Liu, {Tsan Zon} and Yu-Jia Chang",
year = "2010",
month = "2",
doi = "10.1245/s10434-009-0718-8",
language = "English",
volume = "17",
pages = "603--612",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Glucose-regulated protein 78 Is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma

AU - Chiou, Jeng-Fong

AU - Tai, Cheng-Jeng

AU - Huang, Ming-Te

AU - Wei, Po-Li

AU - Wang, Yu Huei

AU - An, Jane

AU - Wu, Chih-Hsiung

AU - Liu, Tsan Zon

AU - Chang, Yu-Jia

PY - 2010/2

Y1 - 2010/2

N2 - Background: Sorafenib is a newly established cancer drug found to be an effective systemic treatment for advanced hepatocellular carcinoma (HCC). However, little is known about any potential effectors that modify tumor cell sensitivity towards sorafenib. Here, we present the first evidence that glucose-regulated protein 78 (GRP78) is intimately associated with acquisition of resistance towards sorafenib. Methods: The role of GRP78 in acquisition of resistance towards sorafenib was determined using HepJ5 (a GRP78-overexpressing subline) and HepG2 as its pair-matched control. RNA interference in cancer cells was applied to determine the influence of GRP78 expression on sensitivity to sorafenib treatment. Results: We found that HepG2 cells exhibited higher sensitivity toward sorafenib, with 50% inhibition concentration (IC 50) >20 μΜ for HepJ5 and 4.8 μM for HepG2. Specifically, when HepG2 cells received 20 μM sorafenib treatment for 24 h, over 80% of cells underwent apoptosis compared with only 32% of HepJ5 cells under similar experimental conditions. Similarly, GRP78 knockdown in HepJ5 cells by small interfering RNA (siRNA) technique enhanced the efficacy of sorafenib-mediated cell death. This was reflected by a shift of IC50 values from >20 μM to 4.8 μM. Conclusions: GRP78 is a positive modifier for sorafenib resistance acquisition in HCC and represents a prime target for overcoming sorafenib resistance.

AB - Background: Sorafenib is a newly established cancer drug found to be an effective systemic treatment for advanced hepatocellular carcinoma (HCC). However, little is known about any potential effectors that modify tumor cell sensitivity towards sorafenib. Here, we present the first evidence that glucose-regulated protein 78 (GRP78) is intimately associated with acquisition of resistance towards sorafenib. Methods: The role of GRP78 in acquisition of resistance towards sorafenib was determined using HepJ5 (a GRP78-overexpressing subline) and HepG2 as its pair-matched control. RNA interference in cancer cells was applied to determine the influence of GRP78 expression on sensitivity to sorafenib treatment. Results: We found that HepG2 cells exhibited higher sensitivity toward sorafenib, with 50% inhibition concentration (IC 50) >20 μΜ for HepJ5 and 4.8 μM for HepG2. Specifically, when HepG2 cells received 20 μM sorafenib treatment for 24 h, over 80% of cells underwent apoptosis compared with only 32% of HepJ5 cells under similar experimental conditions. Similarly, GRP78 knockdown in HepJ5 cells by small interfering RNA (siRNA) technique enhanced the efficacy of sorafenib-mediated cell death. This was reflected by a shift of IC50 values from >20 μM to 4.8 μM. Conclusions: GRP78 is a positive modifier for sorafenib resistance acquisition in HCC and represents a prime target for overcoming sorafenib resistance.

UR - http://www.scopus.com/inward/record.url?scp=77149157802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77149157802&partnerID=8YFLogxK

U2 - 10.1245/s10434-009-0718-8

DO - 10.1245/s10434-009-0718-8

M3 - Article

C2 - 19830497

AN - SCOPUS:77149157802

VL - 17

SP - 603

EP - 612

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -